ArticleScientific reports2024

Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab.

Yuki Kasahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.